Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Jul 1;25(1):855.
doi: 10.1186/s12879-025-11209-6.

Understanding barriers and facilitators to doxycycline post-exposure prophylaxis adherence among young women in western kenya: a qualitative study

Benn Kwach #  1 , Zachary Kwena #  2 , Lauren R Violette  3   4 , Bernard Rono  2 , Josephine B Odoyo  2 , Kevin Oware  2 , Elizabeth A Bukusi  2   5   6 , Jared M Baeten  5 , Lucy Mkandawire-Valhmu  7 , Jenell Stewart  8   9 ; dPEP Kenya Study Team
Collaborators, Affiliations
Randomized Controlled Trial

Understanding barriers and facilitators to doxycycline post-exposure prophylaxis adherence among young women in western kenya: a qualitative study

Benn Kwach et al. BMC Infect Dis. .

Abstract

Sexually transmitted infection (STI) rates are high globally, particularly in regions like sub-Saharan Africa, where there is also a disproportionate burden of HIV. Doxycycline post-exposure prophylaxis (doxyPEP) is a novel strategy intended to prevent bacterial STIs following potential exposure. The dPEP Kenya Study, the first trial of doxyPEP for STI prevention among cisgender women, found that doxyPEP did not reduce STIs in the setting of low use of doxyPEP by objective drug concentrations. To assess barriers and facilitators to doxyPEP adherence, we explored participants' experiences during the dPEP Kenya Study. We conducted serial in-depth interviews (n = 40) and 4 focus group discussions (n = 29) of participants randomized to take doxyPEP. Transcripts were analyzed using an inductive content analysis approach. Side effects, such as nausea from taking doxyPEP on an empty stomach, dosage interpretation challenges, pill burden, and concerns about stigma and partner reactions hindered adherence. Support from partners, family, and peers, familiarity with doxycycline, and the use of discreet pill carriers facilitated doxyPEP use. Decreasing dosage frequency, promoting the use of discreet pill carriers, and addressing stigma through community-driven communication strategies may improve future doxyPEP uptake and adherence. Clinical trial number. This trial was registered in the ClinicalTrials.gov under registration number, NCT04050540 on 06th August 2019.

Keywords: Adherence; Barriers; DoxyPEP; Facilitators; HIV; Kenya; Pre-Exposure Prophylaxis; Qualitative Study; STIs; Young Women.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: The study received ethical approval from the Scientific Ethics Review Unit at the Kenya Medical Research Institute (KEMRI) and the University of Washington’s Institutional Review Board (IRB) and was conducted in accordance with the Declaration of Helsinki. All participants provided written informed consent before participation, and confidentiality was maintained throughout the study. Consent for publication: Not applicable. Competing interests: JMB is currently an employee of Gilead Sciences outside of this work. All other authors do not have competing interest.

Figures

Fig. 1
Fig. 1
The dPEP Kenya Study design summary
See this image and copyright information in PMC

References

    1. WHO, "Global total incidence of curable sexually transmitted infections (Trichomonas vaginalis,Treponema pallidum, Neisseria gonorrhoeae, and Chlamydia trachomatis) among adolescents and adults, 15 -49 years old, 2020," 2021.
    1. Katz D. STI and HIV incidence among women in PrEP trials. Sexually Transmitted Infections. 2019;95(2):125–9.
    1. Dat C. STI prevalence and impact on reproductive health in young women. Lancet Glob Health. 2021;9(5):e620–9.
    1. Nadelman RB, Nowakowski J, Fish D, Falco RC, Freeman K, McKenna D, Welch P, Marcus R, Agüero-Rosenfeld ME, Dennis DT, Wormser GP. Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med. 2001;345(2):79–84. 10.1056/NEJM200107123450201. - PubMed
    1. Luetkemeyer AF, Donnell D, Dombrowski JC, Cohen S, Grabow C, Brown CE, Malinski C, Perkins R, Nasser M, Lopez C, Vittinghoff E, Buchbinder SP, Scott H, Charlebois ED, Havlir DV, Soge OO, Celum C. Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections. N Engl J Med. 2023;388(14):1296–306. 10.1056/nejmc2306480. - PMC - PubMed

Publication types

Associated data